

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



JACOBIO PHARMACEUTICALS GROUP CO., LTD.

加科思藥業集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1167)

VOLUNTARY ANNOUNCEMENT INVESTIGATIONAL NEW DRUG (IND) APPROVAL FOR PARP7 INHIBITOR JAB-26766 IN CHINA

This announcement is made by JACOBIO PHARMACEUTICALS GROUP CO., LTD. (the “**Company**” or “**Jacobio**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders of the Company and potential investors about the latest business advancement of the Group.

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company is pleased to announce that the Company has received Investigational New Drug (IND) approval of its self-developed drug JAB-26766 (PARP7 inhibitor) from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China. The Group plans to initiate a Phase I/IIa advanced solid tumors clinical trial in China.

PARP7 inhibitors target immuno-oncology (I/O) signaling pathway and can be used to treat various solid tumors such as squamous non-small cell lung cancer (NSCLC), and head and neck squamous cell carcinomas (HNSCC). Studies show that PARP7 inhibitors have the potential to directly inhibit tumor growth and enhance the anti-tumor immune response. JAB-26766 is an orally administered small-molecule with significant anti-tumor activity against a variety of tumor models in mice.

PARP7 is located downstream of STING signaling pathway, and JAB-26766 has potential to combine with Jacobio’s self-developed CD73 STING-iADC. JAB-26766 also has the potential to be used in combination with PD-(L)1 monoclonal antibodies to bring more treatment options to patients.

Jacobio is committed to developing global first-in-class drugs, and key programs are targeting the top three worldwide. As of the date of this announcement, there is only one PARP7 inhibitor in Phase I clinical stage globally.

ABOUT JACOBIO

Jacobio is committed to developing and providing new and innovative products and solutions to improve patients' health. Our pipeline revolves around novel molecular targets on six major signalling pathways: KRAS, immune checkpoints, tumor metabolism, P53, RB and MYC. We aim for our key projects to be among the top three in the world. Our vision is to become a global leader recognized for our impact in drug R&D together with our partners. Jacobio has R&D centers in Beijing, Shanghai and Boston with our Induced Allosteric Drug Discovery Platform (IADDP) and our immunostimulatory antibody-drug conjugate (iADC) Platform.

Warning under Rule 18A.08(3) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that JAB-26766 will ultimately be successfully developed and marketed by the Company. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company. Please visit www.jacobiopharma.com for more information.

By Order of the Board
JACOBIO PHARMACEUTICALS GROUP CO., LTD.
Yinxiang WANG
Chairman

Hong Kong, June 8, 2023

As at the date of this announcement, the Board comprises Dr. Yinxiang WANG as Chairman and executive Director, Ms. Xiaojie WANG and Ms. Yunyan HU as executive Directors, Ms. Yanmin TANG, Dr. Dong LYU and Dr. Te-li CHEN as non-executive Directors, and Dr. Ruilin SONG, Dr. Bai LU and Dr. Ge WU as independent non-executive Directors.